Astraveus, a Paris, France-based creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, raised €16.5M in Seed funding.
The round was led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture. Following the fundraising, Alain Huriez of Adbio partners, Christian Uhrich of M Ventures, Fiona MacLaughlin of JJDC Inc., and Laurent Higueret of Bpifrance Large Venture will be joining the board of directors.
The company intends to use the funds to advance the development of its technology and expand the team.
Founded in 2016 by Jérémie Laurent, CEO, Astraveus is developing cell and gene therapy (CGT) manufacturing solutions. Its cell foundries miniaturize and automate cell and gene therapy manufacturing in a, modular, end-to-end, microfluidic solution that mimics the elegance of natural systems. The process optimization of the platform enables the replication of optimal manufacturing, delivering therapies in an efficient manner, using fewer materials and with reduced environmental impact.
FinSMEs
27/06/2023